YMU1

YMU1

CAT N°: 21981
Price:

From 128.00 108.80

YMU1 is an inhibitor of thymidylate kinase (TMPK; IC50 = 610 nM).{36989} It is selective for thymidylate kinase over thymidine kinase 1. YMU1 (2 and 10 µM) reduces deoxythymidine triphosphate (dTTP) levels by 30-40% in p58-/- HCT116 cells without affecting dATP, dGTP, or dCTP levels. It also sensitizes a variety of cancer cell lines to doxorubicin (Item No. 15007), including p53+/+ and p53-/- HCT116, HT-29, SaoS2, MDA-MB-231, and MDA-MB-468 cells. YMU1 reduces tumor growth in a p53-/- HCT116 mouse xenograft model when administered at a dose of 5 mg/kg three times per week for four weeks.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 4-[2-(4,6-dimethyl-3-oxoisothiazolo[5,4-b]pyridin-2(3H)-yl)acetyl]-1-piperazinecarboxylic acid, ethyl ester
  • Correlated keywords
    • 1380297-17-5 YMU-1 HCT116 TK-1 p-53 HT29 Sao-S2 SaoS-2 MDAMB-231 MDAMB231 MDAMB-468 MDAMB468
  • Product Overview:
    YMU1 is an inhibitor of thymidylate kinase (TMPK; IC50 = 610 nM).{36989} It is selective for thymidylate kinase over thymidine kinase 1. YMU1 (2 and 10 µM) reduces deoxythymidine triphosphate (dTTP) levels by 30-40% in p58-/- HCT116 cells without affecting dATP, dGTP, or dCTP levels. It also sensitizes a variety of cancer cell lines to doxorubicin (Item No. 15007), including p53+/+ and p53-/- HCT116, HT-29, SaoS2, MDA-MB-231, and MDA-MB-468 cells. YMU1 reduces tumor growth in a p53-/- HCT116 mouse xenograft model when administered at a dose of 5 mg/kg three times per week for four weeks.

We also advise you